Kindstar Globalgene Technology, Inc. (9960) AI Stock Analysis

• Market Cap: HK$1.49B
• Dividend Yield: 1.25%
• Average Volume (3M): 1.18M
• Price to Earnings (P/E): 130.8
• Beta (1Y): 0.54
• Revenue Growth: -6.00%
• EPS Growth: -232.11%
• Country: HK
• Employees: 3,011
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Care Facilities
• EPS (TTM): -0.08
• Shares Outstanding: 1,040,758,400
• 10 Day Avg. Volume: 819,000
• 30 Day Avg. Volume: 1,181,833
• PEG Ratio: 0.19
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: HK$1.50 ▲(4.90%Upside)

The stock's overall score is primarily influenced by its mixed financial performance and low valuation. While there is some positive technical momentum, the company's current unprofitability and cash flow challenges weigh heavily on its potential attractiveness.

Kindstar Globalgene Technology, Inc. Business Overview & Revenue Model

Company Description

Kindstar Global (Beijing) Technology, Inc. provides medical esoteric testing services to hospitals in China. Its services include medical research, drug trial, and translational medicine research services for physicians, medical science and technology institutions, specialty and general hospitals, and pharmaceutical companies. The company's lab platforms comprise flow cytometry, cytogenetic, medical genomics, molecular biology, hematopathology, mass spectrum, pathology, clinical immunology, microbiology, and scientific research laboratories. It provides tests in blood, tumor, and genetics; and cardiovascular, cerebrovascular, infectious, and autoimmune diseases, as well as in internal medicine, surgery, gynecology, pediatrics, and other specialties. The company was founded in 2003 and is headquartered in in Wuhan, China.

How the Company Makes Money

Kindstar Globalgene Technology, Inc. generates revenue primarily through the provision of its diagnostic testing services. The company charges healthcare providers and medical institutions for conducting specialized genetic and molecular diagnostic tests. These services are often billed on a per-test basis, allowing the company to earn income based on the volume and complexity of tests conducted. Additionally, Kindstar may engage in partnerships with hospitals, clinics, and research institutions to expand its service offerings and reach more patients. Such collaborations can lead to increased test orders and service fees. The company may also explore research collaborations or grants that support the development of new diagnostic technologies, creating potential supplementary revenue streams.

Kindstar Globalgene Technology, Inc. Financial Statement Overview

Summary

Mixed financial health with stable balance sheet but challenges in income statement and cash flow. Operational inefficiencies and negative cash flows hinder financial performance.

Income Statement

The income statement reveals fluctuating revenue, with a noticeable decline of 4.1% from 2022 to 2023. Despite a positive EBITDA in 2023, the EBIT and net income margins remain negative, indicating ongoing operational inefficiencies. The gross profit margin has also decreased from 43.5% in 2022 to 45.4% in 2023, reflecting pressure on profitability. These factors contribute to a moderate income statement score.

Balance Sheet

The balance sheet shows strong equity levels, with an equity ratio of approximately 73.8% in 2023. The debt-to-equity ratio is low at 0.07 in 2023, suggesting conservative leverage usage. However, the decrease in stockholders' equity from 2022 to 2023 indicates potential challenges in maintaining capital strength. Overall, the balance sheet remains relatively stable but signals caution on equity erosion.

Cash Flow

Cash flow analysis highlights significant challenges, with operating cash flow turning negative in 2023 and free cash flow also remaining negative. This indicates cash generation issues, compounded by zero capital expenditure reporting, which may impact future growth. The free cash flow to net income ratio is not calculable due to negative net income. These factors result in a lower cash flow score.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	927.57M	967.26M	1.39B	930.67M	891.39M
Gross Profit	439.56M	451.13M	603.05M	485.77M	460.98M
EBITDA	-115.25M	126.38M	150.72M	-1.39B	-909.23M
Net Income	-54.59M	41.29M	75.46M	-1.45B	-974.02M
Balance Sheet
Total Assets	3.77B	3.67B	3.73B	3.19B	1.58B
Cash, Cash Equivalents and Short-Term Investments	1.66B	2.03B	2.00B	2.15B	956.29M
Total Debt	398.36M	194.29M	199.86M	18.19M	85.39M
Total Liabilities	950.51M	774.23M	871.62M	464.15M	3.41B
Stockholders Equity	2.78B	2.87B	2.83B	2.72B	-1.84B
Cash Flow
Free Cash Flow	-179.57M	-189.65M	-102.90M	-220.23M	46.68M
Operating Cash Flow	-44.12M	-14.78M	21.41M	68.03M	73.46M
Investing Cash Flow	-1.21B	854.92M	-1.35B	-666.06M	-121.96M
Financing Cash Flow	144.63M	-82.83M	97.64M	1.59B	851.92M

Kindstar Globalgene Technology, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.43
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9960, the sentiment is Positive. The current price of 1.43 is above the 20-day moving average (MA) of 1.38, above the 50-day MA of 1.35, and above the 200-day MA of 1.25, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 54.12 is Neutral, neither overbought nor oversold. The STOCH value of 61.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9960.

Kindstar Globalgene Technology, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1526	67 Neutral	HK$1.70B	5.28	24.13%	4.17%	-3.85%	-19.28%
3689	61 Neutral	HK$611.94M	36.82	1.07%	4.86%	-1.20%	-87.51%
3886	61 Neutral	HK$1.68B	―	-6.55%	0.48%	0.04%	-4.88%
1518	59 Neutral	HK$410.00M	7.90	8.82%	2.19%	-10.82%	-44.11%
Sector *	58 Neutral	£4.85B	6.57	-62.36%	101.97%	34.03%	6.31%
9960	51 Neutral	HK$1.49B	130.77	-1.93%	1.25%	-6.00%	-232.11%
3869	48 Neutral	HK$718.61M	―	-10.78%	―	-0.95%	-128.35%

Kindstar Globalgene Technology, Inc. Corporate Events

Kindstar Globalgene Announces Board Changes

Kindstar Globalgene Technology, Inc., a company incorporated in the Cayman Islands, announced changes to its board of directors effective June 5, 2025. Ms. Huang Lu and Mr. Gu Huaming have been appointed as members of the Nomination Committee, enhancing the governance structure of the company. This adjustment reflects the company’s ongoing efforts to strengthen its leadership and improve its strategic decision-making processes.

Kindstar Globalgene Establishes Nomination Committee for Enhanced Governance

Kindstar Globalgene Technology, Inc. has established a Nomination Committee to oversee the appointment and evaluation of its board members and senior management. This move, formalized by the board’s resolution on June 22, 2021, aims to ensure effective governance and strategic alignment within the company, potentially impacting its operational efficiency and stakeholder confidence.

Kindstar Globalgene Successfully Passes All AGM Resolutions

Kindstar Globalgene Technology, Inc. announced that all resolutions proposed at their Annual General Meeting on June 5, 2025, were successfully passed. These resolutions included the re-election of directors, re-appointment of auditors, and authorization for share repurchase and issuance mandates. The approval of these resolutions reflects strong shareholder support and positions the company for continued strategic governance and financial management.

Kindstar Globalgene Announces Virtual AGM and Key Resolutions

Kindstar Globalgene Technology, Inc. has announced its upcoming Annual General Meeting, which will be conducted virtually on June 5, 2025. The meeting will address several key resolutions, including the re-election of directors, the re-appointment of Ernst & Young as auditors, and the authorization for the board to fix directors’ and auditors’ remuneration. Additionally, the company seeks approval for a mandate to repurchase shares and to issue additional shares, which could impact the company’s market operations and shareholder value.